Notice2023-27113
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
December 11, 2023
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 236 (Monday, December 11, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 236 (Monday, December 11, 2023)]
[Notices]
[Page 85894]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-27113]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Theodoric Mattes at 240-627-3827, or
<a href="/cdn-cgi/l/email-protection#087c606d676c677a616b2665697c7c6d7b48666160266f677e"><span class="__cf_email__" data-cfemail="0f7b676a606b607d666c21626e7b7b6a7c4f61666721686079">[email protected]</span></a>. Licensing information may be obtained by
communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished information related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
Vaccine for Cats To Block Toxoplasma Gondii Oocyst Shedding and
Transmission
Description of Technology:
Toxoplasma gondii is the zoonotic causative agent of toxoplasmosis,
a disease of significant concern for pregnant persons and livestock. A
member of the phylum Apicomplexa, Toxoplasma gondii can infect almost
any cell type found in mammals and birds. There are multiple
transmission pathways, including consumption of undercooked meat from
infected animals, consumption of unwashed plants, contaminated water
supplies, blood transfers, and congenital transfer. Felines are
considered the definitive host of Toxoplasma gondii. Direct or indirect
transmission can occur via contact with the stool of infected felines.
Researchers at the National Institute of Allergy and Infectious
Diseases (NIAID), the U.S. Department of Agriculture (USDA), and the
University of South Bohemia ([Ccaron]esk[eacute] Bud[ecaron]jovice,
Czechia) have demonstrated that T. gondii strains lacking expression of
either the intracellular transport protein IFT88 or the CYS-6-type
surface antigen SRS15B prevent the formation of oocysts and have
potential for broad immunity to T. gondii. The inventors propose that
mass inoculation of felines, specifically wild or feral felines, with a
live vaccine developed from these strains could result in a significant
reduction in oocyst production and environment contamination, reducing
further infection in a geographical area. It is also proposed that loss
of IFT88 or SRS15B homologs in other Apicomplexa parasites, like
Neospora, Sarcocystis, or Cryptosporidium could have a similar impact.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications:
<bullet> Live vaccine for felines against Toxoplasma gondii infection
<bullet> Reduction in environmental Toxoplasma gondii oocysts
Competitive Advantages:
<bullet> 100% blocked Toxoplasma gondii oocyst shedding in felines
<bullet> Detectable seroconversion protective against future Toxoplasma
gondii infection
<bullet> Scalable production strain with predictable inactivation of
IFT88 or SRS15B gene
<bullet> Materials available for development or licensing
Development Stage:
<bullet> Pre-Clinical
Inventors: Michael Grigg (NIAID), Aline Sardinha da Silva (NIAID),
Viviana Pszenny (NIAID), Jitender Dubey (USDA), and Julius Luke[scaron]
(University of South Bohemia, Czechia).
Intellectual Property: HHS Reference No. E-118-2023-2. U.S.
Provisional Patent Application No. 63/470,773 filed June 4, 2023.
Licensing Contact: To license this technology, please contact
Theodoric Mattes at 240-627-3827, or <a href="/cdn-cgi/l/email-protection#a9ddc1ccc6cdc6dbc0ca87c4c8ddddccdae9c7c0c187cec6df"><span class="__cf_email__" data-cfemail="abdfc3cec4cfc4d9c2c885c6cadfdfced8ebc5c2c385ccc4dd">[email protected]</span></a>., and
reference E-118-2023-2.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize this technology. For collaboration
opportunities, please contact Theodoric Mattes at 240-627-3827, or
<a href="/cdn-cgi/l/email-protection#e99d818c868d869b808ac784889d9d8c9aa9878081c78e869f"><span class="__cf_email__" data-cfemail="295d414c464d465b404a0744485d5d4c5a69474041074e465f">[email protected]</span></a>.
Dated: December 5, 2023.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2023-27113 Filed 12-8-23; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on December 11, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.